Therapeutic potential of targeting glucose metabolism in glioma stem cells

Bibliography

• Jarzabek MA, Sweeney KJ, Evans RL, et al. Molecular imaging in the. development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary. Drug Discov Today 2013;18:1052-66
   PubMed Web of Science ®Google Scholar
• Mao P, Joshi K, Li J, et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA 2013;110:8644-9
   PubMed Web of Science ®Google Scholar
• Flavahan WA, Wu Q, Hitomi M, et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci 2013;16:1373-82
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73
   PubMed Web of Science ®Google Scholar
• Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110
   PubMed Web of Science ®Google Scholar
• Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012;22:425-37
   PubMed Web of Science ®Google Scholar
• Carro MS, Lim WK, Alvarez MJ, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010;463:318-25
   PubMed Web of Science ®Google Scholar
• Bhat KP, Balasubramaniyan V, Vaillant B, et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 2013;24:331-46
   PubMed Web of Science ®Google Scholar
• Gilbert CA, Ross AH. Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem 2009;108:1031-8
   PubMed Web of Science ®Google Scholar
• Heddleston JM, Hitomi M, Venere M, et al. Glioma stem cell maintenance: the role of the microenvironment. Curr Pharm Des 2011;17:2386-401
   PubMed Web of Science ®Google Scholar
• Ji J, Black KL, Yu JS. Glioma stem cell research for the development of immunotherapy. Neurosurg Clin N Am 2010;21:159-66
   PubMed Web of Science ®Google Scholar
• Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009;15:501-13
   PubMed Web of Science ®Google Scholar
• Clendening JW, Penn LZ. Targeting tumor cell metabolism with statins. Oncogene 2012;31:4967-78
   Google Scholar
• Romero-Garcia S, Lopez-Gonzalez JS, Baez-Viveros JL, et al. Tumor cell metabolism: an integral view. Cancer Biol Ther 2011;12:939-48
   PubMed Web of Science ®Google Scholar
• Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 2009;23:537-48
   PubMed Web of Science ®Google Scholar
• Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 2008;13:472-82
   PubMed Web of Science ®Google Scholar
• Shuch B, Linehan WM, Srinivasan R. Aerobic glycolysis: a novel target in kidney cancer. Expert Rev Anticancer Ther 2013;13:711-19
   PubMed Web of Science ®Google Scholar
• Hagenbuchner J, Kuznetsov AV, Obexer P, Ausserlechner MJ. BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery. Oncogene 2013;32(40):4748-57
   PubMed Web of Science ®Google Scholar
• Lu W, Hu Y, Chen G, et al. Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy. PLoS Biol 2012;10:e1001326
   PubMed Web of Science ®Google Scholar
• Sun Q, Chen X, Ma J, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 2011;108:4129-34
   PubMed Web of Science ®Google Scholar
• Michelakis ED, Sutendra G, Dromparis P, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2010;2:31ra34
   PubMed Web of Science ®Google Scholar
• Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013;340:626-30
   PubMed Web of Science ®Google Scholar
• Kim M, Le H, McInerney MJ, Buckel W. Identification and characterization of re-citrate synthase in Syntrophus aciditrophicus. J Bacteriol 2013;195:1689-96
   PubMed Web of Science ®Google Scholar
• Wise DR, Ward PS, Shay JE, et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci USA 2011;108:19611-16
   PubMed Web of Science ®Google Scholar
• Leonardi R, Subramanian C, Jackowski S, Rock CO. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. J Biol Chem 2012;287:14615-20
   PubMed Web of Science ®Google Scholar
• Wang JB, Erickson JW, Fuji R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010;18:207-19
   PubMed Web of Science ®Google Scholar